{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:13:31Z","timestamp":1787454811342,"version":"build-2736575974"},"reference-count":147,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The clinical application of immune checkpoint inhibitor (ICI) has profoundly reshaped the therapeutic landscape of non-small cell lung cancer (NSCLC), heralding a new era of immunotherapy in oncology. However, despite the durable and remarkable clinical benefits observed in a subset of patients, a considerable proportion exhibit primary or acquired resistance, substantially limiting overall therapeutic efficacy. Immune resistance has emerged as one of the central challenges in ICI-based NSCLC treatment, stemming from an incomplete understanding of ICI mechanisms of action and the highly heterogeneous and dynamically complex nature of the NSCLC tumor microenvironment (TME). This review provides a comprehensive overview of the diverse molecular and cellular mechanisms underlying ICI resistance in NSCLC, highlights recent advances in combination therapeutic strategies aimed at overcoming resistance, and discusses the opportunities and challenges associated with their clinical translation and application.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1691980","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:26:59Z","timestamp":1762324019000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Xuebing","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1002\/mco2.501","article-title":"Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non-small cell lung cancer: A multi-institutional retrospective cohort study","volume":"5","author":"Wu","year":"2024","journal-title":"MedComm (2020)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage iii non-small cell lung cancer: the phase 2 keynote-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00630-6","article-title":"Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage iii non-small-cell lung cancer in China (Gemstone-301): interim results of a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1207","article-title":"Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"29","author":"Thummalapalli","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12789","article-title":"Immunotherapy for lung cancer","volume":"21","author":"Steven","year":"2016","journal-title":"Respirology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage ib-iiia non-small-cell lung cancer (Pearls\/keynote-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00090","article-title":"Immunotherapy: from advanced nsclc to early stages, an evolving concept","volume":"7","author":"Berghmans","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous nsclc (Camel-sq): A phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous nsclc","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100416","article-title":"A randomized phase 2 trial of nivolumab versus nivolumab-ipilimumab combination in egfr-mutant nsclc","volume":"3","author":"Lai","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to pd-1 pathway blockade: recommendations from the first meeting of the sitc immunotherapy resistance taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1186\/s12951-022-01621-4","article-title":"Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of lag3 and tigit improves the treatment efficacy in anti-pd1 resistant lung cancer","volume":"20","author":"Hu","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104258","article-title":"Understanding and overcoming the resistance of cancer to pd-1\/pd-L1 blockade","volume":"145","author":"Shergold","year":"2019","journal-title":"Pharmacol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2022.0407","article-title":"Tumor immune microenvironment and immunotherapy in non-small cell lung cancer: update and new challenges","volume":"13","author":"Xing","year":"2022","journal-title":"Aging Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2806","article-title":"First-line pembrolizumab for non-small cell lung cancer patients with pd-L1 >\/=50% in a multicenter real-life cohort: the pembreizh study","volume":"9","author":"Amrane","year":"2020","journal-title":"Cancer Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for pd-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00676","article-title":"Inducers, attractors and modulators of cd4(+) treg cells in non-small-cell lung cancer","volume":"11","author":"Xie","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6319649","article-title":"Immunosuppressive role of myeloid-derived suppressor cells and therapeutic targeting in lung cancer","volume":"2018","author":"Ma","year":"2018","journal-title":"J Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2206725","article-title":"Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer","volume":"12","author":"Sandstrom Gerdtsson","year":"2023","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"Tgfbeta attenuates tumour response to pd-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"Tgf-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101934","article-title":"Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in nsclc with mature tertiary lymphoid structures","volume":"6","author":"Peyraud","year":"2025","journal-title":"Cell Rep Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting tgf-beta and pd-L1, in second-line treatment of patients with nsclc: results from an expansion cohort of a phase 1 trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1515748","article-title":"Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy","volume":"16","author":"De Lucia","year":"2025","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604310","article-title":"T lymphocyte heterogeneity in nsclc: implications for biomarker development and therapeutic innovation","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000706","article-title":"Stk11 and keap1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort","volume":"5","author":"Papillon-Cavanagh","year":"2020","journal-title":"ESMO Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.035","article-title":"A phase iii study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer","volume":"51","author":"Giaccone","year":"2015","journal-title":"Eur J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine ose2101 versus chemotherapy in hla-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: atalante-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0962","article-title":"A burned-out cd8(+) T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy","volume":"11","author":"Sanmamed","year":"2021","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic pd-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101831","article-title":"Analysis of pd1, lag3, tigit, and tim3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response","volume":"5","author":"Guegan","year":"2024","journal-title":"Cell Rep Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101686","article-title":"Soluble tim-3 serves as a tumor prognostic marker and therapeutic target for cd8(+) T cell exhaustion and anti-pd-1 resistance","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00292-8","article-title":"Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-pd-1 therapy in lung cancer","volume":"3","author":"Liu","year":"2022","journal-title":"Nat Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by pd-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2022.07.004","article-title":"Tcf1(+)Pd-1(+) tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer","volume":"174","author":"Koh","year":"2022","journal-title":"Eur J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific til in anti-pd-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002591","article-title":"Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies","volume":"9","author":"Nishikawa","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/2326-6066.CIR-24-0184","article-title":"Lung cancer-intrinsic sox2 expression mediates resistance to checkpoint blockade therapy by inducing treg-dependent cd8+ T-cell exclusion","volume":"13","author":"Torres-Mejia","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001749","article-title":"Therapeutic depletion of ccr8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-pd-1 therapy","volume":"9","author":"Van Damme","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","article-title":"A single-cell atlas reveals immune heterogeneity in anti-pd-1-treated non-small cell lung cancer","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"eadg1487","DOI":"10.1126\/sciimmunol.adg1487","article-title":"Lung tumor-infiltrating T(Reg) have divergent transcriptional profiles and function linked to checkpoint blockade response","volume":"8","author":"Dykema","year":"2023","journal-title":"Sci Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70029","article-title":"High antigenicity for T(Reg) cells confers resistance to pd-1 blockade therapy via high pd-1 expression in T(Reg) cells","volume":"116","author":"Matsuura","year":"2025","journal-title":"Cancer Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd1616","article-title":"Overcoming microenvironmental resistance to pd-1 blockade in genetically engineered lung cancer models","volume":"13","author":"Martinez-Usatorre","year":"2021","journal-title":"Sci Transl Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003890","article-title":"Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-pd1\/pd-L1 antibodies","volume":"10","author":"Larroquette","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01998-y","article-title":"Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer","volume":"57","author":"Yan","year":"2025","journal-title":"Nat Genet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216021","article-title":"Macrophage xct deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer","volume":"554","author":"Tang","year":"2023","journal-title":"Cancer Lett"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1390","article-title":"Antibody-fc\/fcr interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to pd-1\/pd-L1 blockade","volume":"25","author":"Lo Russo","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.866561","article-title":"High levels of circulating monocytic myeloid-derived suppressive-like cells are associated with the primary resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: an exploratory analysis","volume":"13","author":"Bronte","year":"2022","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010612","article-title":"Cell-intrinsic pd-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through il-6\/jak\/stat3 in pd-L1-high lung cancer","volume":"13","author":"Jeong","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2059876","article-title":"Cxcl5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer cd8 T cells and limits the efficacy of checkpoint inhibitors","volume":"11","author":"Simoncello","year":"2022","journal-title":"Oncoimmunology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2022.10.012","article-title":"Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis","volume":"174","author":"Isomoto","year":"2022","journal-title":"Lung Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3564","article-title":"Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in lkb1-deficient non-small cell lung cancer","volume":"81","author":"Li","year":"2021","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","article-title":"Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms","volume":"39","author":"Hu","year":"2021","journal-title":"Cancer Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2021.05.009","article-title":"Cancer-associated fibroblasts in non-small cell lung cancer: recent advances and future perspectives","volume":"514","author":"Zhang","year":"2021","journal-title":"Cancer Lett"},{"key":"B63","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","article-title":"Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102017","article-title":"Interferon-gamma-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer","volume":"6","author":"Cao","year":"2025","journal-title":"Cell Rep Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"eadh8005","DOI":"10.1126\/scitranslmed.adh8005","article-title":"Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer","volume":"15","author":"Herzog","year":"2023","journal-title":"Sci Transl Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired hla class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000974","article-title":"Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (Nsclc) and melanoma","volume":"8","author":"Thompson","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific hla loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic hla class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13384","article-title":"B2m gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy","volume":"164","author":"Zhao","year":"2021","journal-title":"Immunology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to pd-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Transl Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113295","article-title":"Keap1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep"},{"key":"B73","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0318-2","article-title":"Molecular landmarks of tumor hypoxia across cancer types","volume":"51","author":"Bhandari","year":"2019","journal-title":"Nat Genet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231106","article-title":"Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"222","author":"Robles-Oteiza","year":"2025","journal-title":"J Exp Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41698-024-00626-6","article-title":"Spatial itme analysis of kras mutant nsclc and immunotherapy outcome","volume":"8","author":"Zhao","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.005","article-title":"Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of kras(G12d)-mutated non-small-cell lung cancer","volume":"33","author":"Ricciuti","year":"2022","journal-title":"Ann Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12327","article-title":"Kras-G12d mutation drives immune suppression and the primary resistance of anti-pd-1\/pd-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"Stk11\/lkb1 mutations and pd-1 inhibitor resistance in kras-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009444","article-title":"Lkb1 dictates sensitivity to immunotherapy through skp2-mediated ubiquitination of pd-L1 protein in non-small cell lung cancer","volume":"12","author":"Lv","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of kras-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"key":"B83","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"Stk11\/lkb1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","article-title":"Suppression of sting associated with lkb1 loss in kras-driven lung cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00208-6","article-title":"Ulk1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in lkb1 mutant lung cancer","volume":"2","author":"Deng","year":"2021","journal-title":"Nat Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cmet.2018.02.006","article-title":"Synergy between the keap1\/nrf2 and pi3k pathways drives non-small-cell lung cancer with an altered immune microenvironment","volume":"27","author":"Best","year":"2018","journal-title":"Cell Metab"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic egfr-mutated non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase ii study of pembrolizumab in egfr-mutant, pd-L1+, tyrosine kinase inhibitor naive patients with advanced nsclc","volume":"13","author":"Lisberg","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential pd-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to pd-(L)1 blockade in non-small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14113","article-title":"The immune response-related mutational signatures and driver genes in non-small-cell lung cancer","volume":"110","author":"Chen","year":"2019","journal-title":"Cancer Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3023","article-title":"Pten loss confers resistance to anti-pd-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells","volume":"83","author":"Exposito","year":"2023","journal-title":"Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.031","article-title":"Small cell lung cancer transformation as a mechanism of resistance to pd-1 therapy in kras-mutant lung adenocarcinoma: A report of two cases","volume":"14","author":"Iams","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/LCTT.S173724","article-title":"Non-small cell to small cell lung cancer on pd-1 inhibitors: two cases on potential histologic transformation","volume":"9","author":"Abdallah","year":"2018","journal-title":"Lung Cancer (Auckl)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.09.025","article-title":"Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer","volume":"138","author":"Bar","year":"2019","journal-title":"Lung Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000697","article-title":"Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized","volume":"8","author":"Sehgal","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275957","article-title":"Histological transformation into sclc: an important resistance mechanism of nsclc upon immunotherapy","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13312","article-title":"Histologic transformation of lung cancer during pembrolizumab therapy: A case report","volume":"11","author":"Si","year":"2020","journal-title":"Thorac Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.619371","article-title":"Case report: transformation from non-small cell lung cancer to small cell lung cancer during anti-pd-1 therapy: A report of two cases","volume":"11","author":"Shen","year":"2021","journal-title":"Front Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (Checkmate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002973","article-title":"Phase ii study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-pd-1\/pd-L1 resistant stage iv squamous cell lung cancer (Lung-map substudy S1400f, nct03373760)","volume":"9","author":"Leighl","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107355","article-title":"A multicenter, open-label phase ib\/ii study of cadonilimab (Anti pd-1 and ctla-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (Ak104\u2013202 study)","volume":"184","author":"Zhao","year":"2023","journal-title":"Lung Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07943-7","article-title":"Ctla4 blockade abrogates keap1\/stk11-related resistance to pd-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2024-2726","article-title":"Abstract 2726: A novel trispecific antibody hc010 targeting pd-1\/ctla-4\/vegf for the potential treatment in anti-pd-1 antibody resistant nsclc patients","volume":"84","author":"Jiang","year":"2024","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.36_suppl.397600","article-title":"Arc-7: randomized phase 2 study of domvanalimab + Zimberelimab \u00b1 Etrumadenant versus zimberelimab in first-line, metastatic, pd-L1-high non-small cell lung cancer (Nsclc)","volume":"40","author":"Johnson","year":"2022","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-tigit antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(\u2606)","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100593","article-title":"121p Mk-7684a (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) with\/without Docetaxel in Metastatic Nsclc after Platinum-Chemotherapy (Chemo) and Immunotherapy","volume":"20","author":"Peled","year":"2023","journal-title":"Immuno-Oncology Technol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007854","article-title":"Epithelium\/imcdc2 axis facilitates the resistance of neoadjuvant anti-pd-1 in human nsclc","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e14597","article-title":"A bivalent tim-3\/pd-1 bispecific antibody for the treatment of pd-1 antibody resistant or refractory nsclc","volume":"40","author":"Liu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004440","article-title":"Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to pd-1 axis blockers in non-small cell lung cancer","volume":"10","author":"Lopez de Rodas","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3100","article-title":"Initial results from a phase ii study (Tacti-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (Soluble lag-3 protein) and pembrolizumab","volume":"38","author":"Felip","year":"2020","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006896","article-title":"Ccl21-dc in situ vaccination in murine nsclc overcomes resistance to immunotherapy and generates systemic tumor-specific immunity","volume":"11","author":"Salehi-Rad","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-0435","article-title":"Characteristics of a ccl21 gene-modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer","volume":"24","author":"Oh","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101479","article-title":"Cxcl9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34382","article-title":"Immunotherapies targeting neoantigens are effective in pd-1 blockade-resistant tumors","volume":"152","author":"Sun","year":"2023","journal-title":"Int J Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine neo-pv-01 with chemotherapy and anti-pd-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-pd-1-resistant metastatic lung cancer: A phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1022-2","article-title":"Targeting tyro3, axl and mertk (Tam receptors): implications for macrophages in the tumor microenvironment","volume":"18","author":"Myers","year":"2019","journal-title":"Mol Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"S949","DOI":"10.1016\/j.annonc.2021.08.1796","article-title":"1191o mrtx-500: phase ii trial of sitravatinib (Sitra) + Nivolumab (Nivo) in patients (Pts) with non-squamous (Nsq) non-small cell lung cancer (Nsclc) progressing on or after prior checkpoint inhibitor (Cpi) therapy","volume":"32","author":"Leal","year":"2021","journal-title":"Ann Oncol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"Sapphire: phase iii study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.041","article-title":"Oa06.03 saffron-301: tislelizumab plus sitravatinib in advanced\/metastatic nsclc progressing on\/after chemotherapy and anti-pd-(L)1","volume":"19","author":"Zhou","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9134","article-title":"Contact-01: A phase iii, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (Mnsclc) previously treated with pd-L1\/pd-1 inhibitors and platinum-containing chemotherapy","volume":"39","author":"Neal","year":"2021","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"eabn6173","DOI":"10.1126\/sciimmunol.abn6173","article-title":"Pd-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance","volume":"8","author":"van Gulijk","year":"2023","journal-title":"Sci Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.02.029","article-title":"Selective depletion of ccr8+Treg cells enhances the antitumor immunity of cytotoxic T cells in lung cancer by dendritic cells","volume":"20","author":"Chen","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"e1515","DOI":"10.1002\/ctm2.1515","article-title":"Single-cell and spatial transcriptomics reveal postn(+) cancer-associated fibroblasts correlated with immune suppression and tumour progression in non-small cell lung cancer","volume":"13","author":"Chen","year":"2023","journal-title":"Clin Transl Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12967-024-05456-5","article-title":"Egfr mutations induce the suppression of cd8(+) T cell and anti-pd-1 resistance via erk1\/2-P90rsk-tgf-beta axis in non-small cell lung cancer","volume":"22","author":"Huang","year":"2024","journal-title":"J Transl Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08305-z","article-title":"Neutralizing gdf-15 can overcome anti-pd-1 and anti-pd-L1 resistance in solid tumours","volume":"637","author":"Melero","year":"2025","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2176","article-title":"Combined vegf and pd-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer","volume":"78","author":"Meder","year":"2018","journal-title":"Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01598","article-title":"Phase ib\/ii trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.05.020","article-title":"Leap-008: lenvatinib plus pembrolizumab for metastatic nsclc that has progressed after an anti-programmed cell death protein 1 or anti-programmed cell death ligand 1 plus platinum chemotherapy","volume":"20","author":"Leighl","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02166","article-title":"Contact-01: A randomized phase iii trial of atezolizumab + Cabozantinib versus docetaxel for metastatic non-small cell lung cancer after a checkpoint inhibitor and chemotherapy","volume":"42","author":"Neal","year":"2024","journal-title":"J Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00912","article-title":"Phase ii randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-map S1800a","volume":"40","author":"Reckamp","year":"2022","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"Ak112, a novel pd-1\/vegf bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (Nsclc): an open-label, multicenter, phase ii trial","volume":"62","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from keynote-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous nsclc (Impower131): results from a randomized phase iii trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous nsclc: protocol-specified final analysis of keynote-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in advanced nsclc: 2-year follow-up from the phase 3 empower-lung 3 part 2 trial","volume":"18","author":"Makharadze","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of car-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"B142","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","article-title":"The superior efficacy of anti-pd-1\/pd-L1 immunotherapy in kras-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity","volume":"470","author":"Liu","year":"2020","journal-title":"Cancer Lett"},{"key":"B143","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","article-title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with pd-L1 50% or more (Empower-lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Ozguroglu","year":"2023","journal-title":"Lancet Oncol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12951-025-03129-z","article-title":"Enzymatically responsive nanocarriers targeting pd-1 and tgf-beta pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy","volume":"23","author":"Yen","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213434","article-title":"A novel P53 nanomedicine reduces immunosuppression and augments anti-pd-1 therapy for non-small cell lung cancer in syngeneic mouse models","volume":"11","author":"Kim","year":"2022","journal-title":"Cells"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase iii poseidon study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (Checkmate 9la): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1691980\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:27:00Z","timestamp":1762324020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1691980\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":147,"alternative-id":["10.3389\/fimmu.2025.1691980"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1691980","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1691980"}}